{"success":true,"data":{"pressRelease":{"id":"133197","rtpr_id":"nGNX8716","ticker":"TEVA","exchange":"","all_tickers":["TEVA"],"title":"Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September","author":"Globe Newswire","published_at":"2026-09-01T20:30:00.546Z","article_body":"TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical\nIndustries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis,\nTeva's President and CEO, will present at three upcoming investor conferences\nin September as follows:\n* Morgan Stanley 24th Annual Global Healthcare Conference\nMonday, September 14, 2026, at 8:30 A.M. Eastern Time (ET)\n\n\n* J.P. Morgan U.S. All Stars Conference \nTuesday, September 22, 2026, at 8:00 A.M. British Summer Time (3:00 A.M. ET)\n\n\n* BofA Global Healthcare Conference 2026  \nWednesday, September 23, 2026, at 10:55 A.M. British Summer Time (5:55 A.M.\nET)\nTo access a live webcast of the presentation, visit Teva’s Investor\nRelations website at https://ir.tevapharm.com/Events-and-Presentations.\n\nAn archived version of the webcast will be available within 24 hours after the\nend of the live discussion.\n\nAbout Teva\n\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis Document and the presentation at the conferences may contain\nforward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995, which are based on management’s current\nbeliefs and expectations and are subject to substantial risks and\nuncertainties, both known and unknown, that could cause our future results,\nperformance or achievements to differ significantly from that expressed or\nimplied by such forward-looking statements. You can identify these\nforward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “estimate,” “target,” “may,”\n“project,” “guidance,” “intend,” “plan,” “believe” and\nother words and terms of similar meaning and expression in connection with any\ndiscussion of future operating or financial performance. Important factors\nthat could cause or contribute to such differences include risks relating to:\nour ability to successfully compete in the marketplace, including our ability\nto successfully execute on our Pivot to Growth strategy, including to expand\nour innovative and biosimilar medicines pipeline and to profitably\ncommercialize our innovative medicines and biosimilar portfolio, whether\norganically or through business development, to sustain and focus our\nportfolio of generic medicines, and to execute on our organizational\ntransformation and to achieve expected cost savings; our significant\nindebtedness; our business and operations in general; compliance, regulatory\nand litigation matters; other financial and economic risks; and other factors\ndiscussed in our Quarterly Report on Form 10-Q for the second quarter of 2026\nand in our Annual Report on Form 10-K for the year ended December 31, 2025,\nincluding in the sections captioned “Risk Factors,” “Other\nInformation” and “Forward Looking Statements.” Forward-looking\nstatements speak only as of the date on which they are made, and we assume no\nobligation to update or revise any forward-looking statements or other\ninformation contained herein, whether as a result of new information, future\nevents or otherwise. You are cautioned not to put undue reliance on these\nforward-looking statements.\n\nTeva Media Inquiries \nTevaCommunicationsNorthAmerica@tevapharm.com\n\nTeva Investor Relations Inquiries\nTevaIR@Tevapharm.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c2001734-949b-4cc2-8021-b4b64eda1f13)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8716","title":"Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September","author":"Globe Newswire","ticker":"TEVA","created":"2026-09-01T20:30:00.546Z","tickers":["TEVA"],"exchange":"","article_body":"TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical\nIndustries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis,\nTeva's President and CEO, will present at three upcoming investor conferences\nin September as follows:\n* Morgan Stanley 24th Annual Global Healthcare Conference\nMonday, September 14, 2026, at 8:30 A.M. Eastern Time (ET)\n\n\n* J.P. Morgan U.S. All Stars Conference \nTuesday, September 22, 2026, at 8:00 A.M. British Summer Time (3:00 A.M. ET)\n\n\n* BofA Global Healthcare Conference 2026  \nWednesday, September 23, 2026, at 10:55 A.M. British Summer Time (5:55 A.M.\nET)\nTo access a live webcast of the presentation, visit Teva’s Investor\nRelations website at https://ir.tevapharm.com/Events-and-Presentations.\n\nAn archived version of the webcast will be available within 24 hours after the\nend of the live discussion.\n\nAbout Teva\n\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis Document and the presentation at the conferences may contain\nforward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995, which are based on management’s current\nbeliefs and expectations and are subject to substantial risks and\nuncertainties, both known and unknown, that could cause our future results,\nperformance or achievements to differ significantly from that expressed or\nimplied by such forward-looking statements. You can identify these\nforward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “estimate,” “target,” “may,”\n“project,” “guidance,” “intend,” “plan,” “believe” and\nother words and terms of similar meaning and expression in connection with any\ndiscussion of future operating or financial performance. Important factors\nthat could cause or contribute to such differences include risks relating to:\nour ability to successfully compete in the marketplace, including our ability\nto successfully execute on our Pivot to Growth strategy, including to expand\nour innovative and biosimilar medicines pipeline and to profitably\ncommercialize our innovative medicines and biosimilar portfolio, whether\norganically or through business development, to sustain and focus our\nportfolio of generic medicines, and to execute on our organizational\ntransformation and to achieve expected cost savings; our significant\nindebtedness; our business and operations in general; compliance, regulatory\nand litigation matters; other financial and economic risks; and other factors\ndiscussed in our Quarterly Report on Form 10-Q for the second quarter of 2026\nand in our Annual Report on Form 10-K for the year ended December 31, 2025,\nincluding in the sections captioned “Risk Factors,” “Other\nInformation” and “Forward Looking Statements.” Forward-looking\nstatements speak only as of the date on which they are made, and we assume no\nobligation to update or revise any forward-looking statements or other\ninformation contained herein, whether as a result of new information, future\nevents or otherwise. You are cautioned not to put undue reliance on these\nforward-looking statements.\n\nTeva Media Inquiries \nTevaCommunicationsNorthAmerica@tevapharm.com\n\nTeva Investor Relations Inquiries\nTevaIR@Tevapharm.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c2001734-949b-4cc2-8021-b4b64eda1f13)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T20:30:00.585301544Z","server_sent_at_ms":1788294600585},"received_at":"2026-09-01T20:30:00.670Z","source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354625/0/en/teva-to-present-at-morgan-stanley-j-p-morgan-and-bofa-investor-conferences-in-september.html"},"analysis":{"id":"122088","press_release_id":"133197","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Teva announced that CEO Richard Francis will present at three investor conferences in September hosted by Morgan Stanley, J.P. Morgan, and BofA.\n\nThe presentations are scheduled for September 14, September 22, and September 23, with live webcasts accessible via the company's Investor Relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance announcement."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Richard Francis","role":"President and CEO"}],"products":[],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA"},{"name":"Morgan Stanley","relationship":"conference organizer"},{"name":"J.P. Morgan","relationship":"conference organizer"},{"name":"BofA","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of attendance at investor conferences with no material financial disclosures or strategic updates."},"tickerRelevance":{"others":[],"primary":"TEVA"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large_cap","eventGravity":"conference_attendance"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Teva announced that CEO Richard Francis will present at three investor conferences in September hosted by Morgan Stanley, J.P. Morgan, and BofA.\n\nThe presentations are scheduled for September 14, September 22, and September 23, with live webcasts accessible via the company's Investor Relations website.","key_figures":null,"named_entities":{"people":[{"name":"Richard Francis","role":"President and CEO"}],"products":[],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA"},{"name":"Morgan Stanley","relationship":"conference organizer"},{"name":"J.P. Morgan","relationship":"conference organizer"},{"name":"BofA","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T21:14:36.838Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"large_cap","eventGravity":"conference_attendance"}},"durationMs":65076,"modelName":"glm-4.7"}}